Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease

[Bolt_Upright]

Now for something completely different!

Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease

prd-journal.com/article/S13...

prd-journal.com/action/show...

prd-journal.com/cms/10.1016...

3.1 Non-motor symptom (NMS) outcomes

Evaluation of the change in MDS-UPDRS Part I (Non-Motor Aspects of Experiences of Daily Living) from baseline to the end of the treatment period revealed that the active group experienced a significantly greater reduction in the overall burden of NMS relative to the placebo treatment group. Therapeutic gains for this assessment were greatest 5 weeks after the cessation of treatment although change scores at both time-points surpassed a previously established minimal clinically important difference (MCID) [[13]

]. Likewise, active CVS treatment subjects demonstrated significantly greater reductions in NMSS total score than the placebo arm subjects at the end of treatment and which again showed the largest therapeutic gains at the 5-week follow-up assessment. Substantive improvements were demonstrated in most NMSS sub-domains. At the individual subject level, 14 of the 16 active PP subjects demonstrated reductions ≥10 points on one or more domains of the NMSS (Supplemental Fig. 4). Supplemental exploratory post-hoc analysis indicated that there were no interactions with sex, age, time since PD diagnosis, time on anti-Parkinsonian medication, or the VAS score and the observed treatment responses for the NMSS total score. Active arm subjects also demonstrated statistically significant improvements in MoCA scores that persisted through the 5-week follow-up.

3.2 Motor symptoms, ADLs and complications

Active arm subjects demonstrated durable improvements in the MDS-UPDRS Part II (motor aspects of experiences of daily living) and Part III (motor exam) scores that were significantly greater than those for the placebo treatment group, with therapeutic gains exceeding the MCIDs [[13]

,[14]

]. Therapeutic responses were not influenced by sex, age, time since diagnosis, time on anti-Parkinsonian medication, or VAS. Statistically significant differences were also observed in the Modified Schwab & England ADL scale, the 10-m self-paced walk and the Timed-Up-and-Go. Active treatment was also associated with reductions in the MDS-UPDRS Part IV (motor complications) driven primarily by reduced dyskinesias (Supplemental Table 2).

[Bolt_Upright]

A durable gain in motor and non-motor symptoms of Parkinson's Disease following repeated caloric vestibular stimulation: A single-case study

core.ac.uk/reader/30712893?...

[Bolt_Upright]

This is the device! I want one. They are not for sale

Even if I did not need one, I would want one anyway. It is so cool.

researchgate.net/figure/CVS...

[Bolt_Upright]

Remember, when you see your doctor, you are suffering from from "migraines". Write it down:

The TNM Device 3.2 was cleared for marketing in the U.S. (ages 12 and older) and the E.U. (adults) for the prevention of episodic migraine. Parkinson’s patients may currently only use the device (TNM Device 4.0) in clinical trials.

[rebtar in reply to Bolt_Upright]

I assume this device has different settings depending on the purpose. How would you know the settings for Parkinson's?

[Bolt_Upright in reply to rebtar]

That is a good point. The article kind of says what the setting are, but getting it to work would probably be a challenge.

[rebtar in reply to Bolt_Upright]

also, have you seen what the difference is between 3.2 and 4.0?

[Bolt_Upright in reply to rebtar]

Sorry no. I think I was lucky to find the 3.2

[Detki in reply to Bolt_Upright]

Good day, where did you purchase TNM Device?

[Bolt_Upright in reply to Detki]

I don't have one. These devices are approved for treating migraines, so a doctor might be able to prescribe one.

[park_bear]

10 point improvement impressive.

[Bolt_Upright in reply to park_bear]

I checked ebay and for $1400 you can buy an old air CVS, but that would only do one ear so you would need to find another (good luck).

I'm pretty sure I could figure out how to do this with water. I'm sure Albert could figure it out.

[kaypeeoh]

So...squirting warm water in one ear and cool water in the other increased dopamine levels?

[House2 in reply to kaypeeoh]

It stimulates vestibular activation of some of the targets of Deep Brain Stimulation,

[Hidden in reply to House2]

So is it your belief than that it addresses symptoms and is not protective?

[House2 in reply to Hidden]

I read somewhere that DBS, increases Brain derived neurotrophic factor

[House2 in reply to Hidden]

pubmed.ncbi.nlm.nih.gov/223...

[Bolt_Upright in reply to House2]

Sharing the title of your link: Subthalamic Nucleus Stimulation Increases Brain Derived Neurotrophic Factor in the Nigrostriatal System and Primary Motor Cortex

[Bolt_Upright in reply to kaypeeoh]

I think it improves brain plasticity.

[Hidden in reply to Bolt_Upright]

Bolt, do you still think it does? Any new info in this?

[Bolt_Upright in reply to Hidden]

I think there is a chance it is disease modifying. If you have migraines you qualify to use this device. You could be another test case for PD. Last I checked, awhile ago, they were starting a new trial in GB. The first trial went well, and I like that they use the term "durable".

[Bolt_Upright in reply to kaypeeoh]

But the device they used does not use water. Or air. It has some kind of electronic cooling/heating element.

[Bolt_Upright]

"CVS treatment involved lying on a 22°-elevated wedge pillow to orient the horizontal semi-circular canal vertically (thereby maximizing vestibular activation)." prd-journal.com/article/S13...